Lawsuit Targets Unicycive Therapeutics Over Securities Fraud Allegations
Investors' rights law firm Rosen Law Firm has initiated a lawsuit against Unicycive Therapeutics, alleging securities fraud. The class action covers purchases made between December 29, 2025, and June 29, 2026.
Unicycive Therapeutics, a NASDAQ-listed biotechnology company, faces legal action following an announcement by Rosen Law Firm, which specializes in investor rights. The firm is seeking investors to join a class-action lawsuit alleging securities fraud.
The lawsuit pertains to purchasers of Unicycive securities who acquired them during the period from December 29, 2025, to June 29, 2026. Rosen Law Firm asserts that the company may have issued misleading statements to investors, resulting in financial losses for those who relied on this information.
Announced in October 2026, the legal proceedings aim to gather evidence and potentially pursue remedies on behalf of affected investors. Individuals who purchased Unicycive securities within the specified timeframe are encouraged to contact Rosen Law Firm for details on how to participate.
Unicycive Therapeutics is engaged in drug development. The allegations brought against the company could impact its market reputation and future financial prospects, particularly in a sector sensitive to regulatory scrutiny and corporate governance.